Literature DB >> 29166782

Screening for the C9ORF72 repeat expansion in a greek frontotemporal dementia cohort.

Chrisoula Kartanou1, Georgia Karadima1, Georgios Koutsis1, Marianthi Breza1, Sokratis G Papageorgiou2, George P Paraskevas3, Elisabeth Kapaki3, Marios Panas1.   

Abstract

The C9orf72 repeat expansion is a common genetic cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) in European populations. A previous study has reported a high frequency of the expansion in Greek ALS. However, no data have been reported on the frequency of the expansion in Greek FTD. Currently, we investigated the frequency of the C9orfF72 expansion in a well-characterized cohort of 64 Greek FTD patients. We detected the C9orf72 repeat expansion in 9.3% of cases. Overall, 27.7% of familial and 2.2% of sporadic cases were expansion-positive. Five out of 6 cases had a diagnosis of behavioral variant FTD. All expansion-positive cases had fairly typical FTD presentations. Clinical features included motor neuron disease, Parkinsonism and hallucinations. We conclude that the overall frequency of C9orf72-positive cases in Greek FTD is high, comparable to Greek ALS, similar to some Western European, but significantly higher than some Mediterranean FTD populations.

Entities:  

Keywords:  C9ORF72; FTD; Frontotemporal dementia; Greek population; frontotemporal lobar degeneration; hexanucleotide repeat expansion

Mesh:

Substances:

Year:  2017        PMID: 29166782     DOI: 10.1080/21678421.2017.1400070

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  1 in total

Review 1.  Primary progressive aphasia and motor neuron disease: A review.

Authors:  Edoardo Nicolò Aiello; Sarah Feroldi; Giulia De Luca; Lucilla Guidotti; Eleonora Arrigoni; Ildebrando Appollonio; Federica Solca; Laura Carelli; Barbara Poletti; Federico Verde; Vincenzo Silani; Nicola Ticozzi
Journal:  Front Aging Neurosci       Date:  2022-09-08       Impact factor: 5.702

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.